Introduction {#s1}
============

Although lung cancer treatment options have improved significantly in the last decade leading to better survival for patients with every stage of the disease, it is still leading cancer related deaths in the United States with 160 thousand deaths each year [@pone.0082241-Siegel1]. With approximately 85% of all cases the most common type of lung cancer is non-small cell lung cancer (NSCLC), which includes adenocarcinoma, squamous cell carcinoma, large cell carcinoma, and bronchioloalveolar carcinoma [@pone.0082241-Ramalingam1]. Similarly to other cancer entities we can expect new molecular subtypes to emerge in the future, as it is now well accepted that the light microscopy based histologic subdivision uses only one of many phenotypic manifestations of the genetic changes that underlie lung cancer development [@pone.0082241-Ramalingam1].

The identification of genes whose altered expression is associated with survival differences might enclose the knowledge to pinpoint those which could serve as indicators of the tumor\'s biological state. In essence there are two possible scenarios for this: such biomarker can either be an individual gene or a signature comprising a set of genes. While numerous individual genes associated with survival have been published in the last thirty years, new microarray-based multigene molecular prognostic models using genomic signatures have only emerged in the last ten years [@pone.0082241-Bhattacharjee1], [@pone.0082241-Beer1], [@pone.0082241-Lu1], [@pone.0082241-Hayes1], [@pone.0082241-Xi1], [@pone.0082241-Guo1], [@pone.0082241-Raponi1], [@pone.0082241-Zhu1], [@pone.0082241-Hou1], [@pone.0082241-Bild1], [@pone.0082241-Yamauchi1], [@pone.0082241-Xie1], [@pone.0082241-Botling1], [@pone.0082241-Lee1], [@pone.0082241-Shedden1], [@pone.0082241-Hammerman1], [@pone.0082241-Lu2]. A pre-requisite for the reproducibility of such genomic signatures is the availability of raw data, which was only ensured by publications of the last six years [@pone.0082241-Raponi1], [@pone.0082241-Zhu1], [@pone.0082241-Hou1], [@pone.0082241-Bild1], [@pone.0082241-Yamauchi1], [@pone.0082241-Xie1], [@pone.0082241-Botling1], [@pone.0082241-Lee1], [@pone.0082241-Shedden1], [@pone.0082241-Hammerman1]. Remarkably, in two cases not the signature as a whole, but genes as each individually important prognostic markers have been identified [@pone.0082241-Botling1], [@pone.0082241-Lu2].

The initial discovery of a prognostic marker must be followed by several validation studies. Then, the results of these are usually synthesized in a meta-analysis including a large number of preferably more than thousand patients. Here, by uniting relevant data from several studies, statistical power is increased and more accurate estimates can be achieved. Several previous meta-analyses endeavored to perform such a meta-analysis of previous studies for solitary gene candidates including VEGF [@pone.0082241-Zhan1], MMP9 [@pone.0082241-Peng1], cyclin E [@pone.0082241-Huang1], survivin [@pone.0082241-Zhang1] and CDK1 [@pone.0082241-Zhang2].

Here, we integrated available genome-level transcriptomic datasets and then used this database to perform a meta-analysis of previously suggested survival associated biomarker-candidates. We also set up a global portal for such meta-analysis enabling express validation of new candidates without large-scale bioinformatic effort in an automated framework.

Materials and Methods {#s2}
=====================

Construction of lung cancer microarray database {#s2a}
-----------------------------------------------

We explored the Cancer Biomedical Informatics Grid (caBIG, <http://cabig.cancer.gov/>, microarray samples are published in the caArray project), the Gene Expression Omnibus (GEO, <http://www.ncbi.nlm.nih.gov/geo/>) and The Cancer Genome Atlas (TCGA, <http://cancergenome.nih.gov>) to identify lung cancer datasets using the keywords "lung", "cancer", "small-cell", "NSCLC", "survival", "GPL96", "GPL3921" and "GPL570" (and the alternative names of the microarray platforms). The search was restricted to publications with simultaneously available microarray gene expression data and published clinical characteristics including survival. To test randomness, a pairwise rank test was performed for the collected clinical data including age, sex, smoking history, histology, stage, grade, success of surgery, radiotherapy and applied chemotherapy for all patients in WinStat 2013. For the pairwise rank test, the samples were first sorted according to datasets. Then, each sample ("X") in the series was compared with all values which occur later in the list of all samples ("Y") - assuming randomness, the probability of X\>Y is 1/2. The correlations between clinical variables and survival were investigated and Kaplan-Meier plots for these were plotted using WinStat 2013. Among the different microarray platforms, Affymetrix HG-U133A (GPL96), HG-U133 Plus 2.0 (GPL570) and HG-U133A 2.0 (GPL3921) were included, because these are regularly used and because these arrays have 22,277 probe sets in common. The use of the same probe sets enables to measure the same gene with similar accuracy, relative scale and dynamic range.

To avoid potential bias due to array errors, we have performed a quality check for all arrays. In this, the background (between 19 and 218), the raw Q (between 0.5 and 14), the percentage of present calls (over 30%), the presence of bioB-/C-/D- spikes, the GAPDH 3′to 5′ ratio (below 4.3) and the beta-actin 3′ to 5′ ratio (below 18) were checked. The threshold values correspond to the 95% range of the arrays as described previously [@pone.0082241-Gyorffy1]. Quality control was not possible for GSE4573 as for this dataset only the MAS5 normalized data was available. A filtering was added to the database to exclude potentially biased arrays. Additionally, we compared all microarray files using the ranked expression of all genes to spot microarrays re-published in different studies.

Set-up of server for online survival calculation {#s2b}
------------------------------------------------

The unprocessed.CEL files were MAS5 normalized in the R environment (<http://www.r-project.org>) using the simpleaffy library (<http://bioinformatics.picr.man.ac.uk/simpleaffy/>). We have selected MAS5 for normalization as it ranked among the best normalization methods when contrasted to the results of RT-PCR measurements in our previous study [@pone.0082241-Gyorffy2]. Moreover, MAS5 can be applied to single arrays, enabling seamless future extensions of the database. For the complete database, only the common probes measured in all three array platforms were retained (n = 22,277). Then, a second scaling normalization was performed to center the mean expression for each array to 1000 - this technique can significantly reduce batch effects. Gene expression and clinical data were integrated using PostgreSQL, an open source object-relational database system (<http://www.postgresql.org/>).

To assess the prognostic value of a gene, each percentile (of expression) between the lower and upper quartiles were computed and the best performing threshold was used as the final cutoff in a univariate Cox regression analysis. Histology, grade, stage, gender and smoking history can be used in the multivariate analysis. However, the multivariate analysis uses less patients as the univariate analysis because not each patients has all clinical information. Kaplan-Meier survival plot and the hazard ratio with 95% confidence intervals and logrank P value were calculated and plotted in R using the "survplot" function of the "survival" Bioconductor package. The R script used by the software to perform the Kaplan-Meier analysis and to identify the best cutoff is available as **[R script S1](#pone.0082241.s002){ref-type="supplementary-material"}**.

The entire computational pathway is made accessible for re-analysis in a platform independent online available software running on a Debian Linux (<http://www.debian.org>) server powered by Apache (<http://www.apache.org>). The scripts on the server-side were developed in PHP, these control the user interface, the requests and the delivery of the results. The RODBC package provides a middleware layer between R and the PostgreSQL database. This platform can be reached over the internet via <http://www.kmplot.com/lung>.

Validation of previously published survival associated biomarkers {#s2c}
-----------------------------------------------------------------

A Pubmed search was performed to identify lung cancer survival associated biomarkers using all combinations of the keywords "lung cancer", "NSCLC", "adenocarcinoma", "squamous cell carcinoma", "survival", "gene expression", "signature" and "meta analysis". Only studies published in English were included. Eligibility criteria also included the investigation of the biomarker in at least 50 patients - biomarkers described in experimental models only were omitted. For each gene/signature the exact conditions in which it was identified have been retrieved, and these have been used as filtering when selecting the patients for the survival analysis.

To visualize the performance of the various biomarkers in datasets including different number of patients, we have generated funnel plots depicting the hazard ratio (and confidence intervals) on the horizontal axis vs. the sample size on the vertical axis for each dataset. We also added an option to the online interface to simultaneously perform the analysis in each of the individual datasets. Finally, significance was set at p\<0.01.

Results {#s3}
=======

Construction of combined lung cancer microarray database {#s3a}
--------------------------------------------------------

We identified all together 1,715 patients, 1,120 in seven GEO datasets, 133 patients in TCGA and 462 patients in caArray. There were no samples repeatedly published. One sample (GSM370984) failed two parameters in the quality control - this array was excluded from all analyses. Additionally, in 215 arrays one parameter was out of the 95% range of all arrays - these arrays can be excluded from analyses by selecting the "exclude outlier arrays" in the online interface. Overall survival was published for 1,405 patients and time to first progression was published for 764 patients. We have collected age, sex, smoking history, histology, stage, grade, success of surgery, radiotherapy and applied chemotherapy for all patients - none of these parameters was significant in the pairwise rank test indicating random distribution of the data. A summary of these clinical properties for each dataset used is presented in [**Table 1**](#pone-0082241-t001){ref-type="table"}. The survival of the patients stratified by subtype, gender, smoking history and stage is presented in [**Figure 1**](#pone-0082241-g001){ref-type="fig"}.

![Survival characteristics of the patients included in the database including histology of adenocarcinoma (adeno), squamous cell carcinoma (SCC) and large cell carcinoma (large), gender, stage (only with overall survival) and smoking history.](pone.0082241.g001){#pone-0082241-g001}

10.1371/journal.pone.0082241.t001

###### Clinical characteristics of the datasets included in the analysis.

![](pone.0082241.t001){#pone-0082241-t001-1}

  Dataset             Platform           Reference            Sample size   Median follow-up (OS)   No. of deaths   Median follow-up (FP)   No. of progressions         Age         Sex (% male)   \% of never smokers   Histology (% A/S/L)   Stage (% 1/2/3/4)   \% surgical margins negative   Grade (% poor/moderate/well)   \% chemotherapy   \% radiotherapy
  ------------------ ---------- ---------------------------- ------------- ----------------------- --------------- ----------------------- --------------------- ----------------- -------------- --------------------- --------------------- ------------------- ------------------------------ ------------------------------ ----------------- -----------------
  GSE4573              GPL96      [@pone.0082241-Raponi1]         130               34.5                 67                  \-                     \-                67±9.8            63%               3.1%                 0/100/0            56/26/18/0                    \-                          17/71/12                   \-                \-
  GSE14814             GPL96        [@pone.0082241-Zhu1]          90                 5.4                 38                  \-                     \-                62±8.5            74%                \-                 31/58/11             50/50/0/0                    \-                             \-                      56%               \-
  GSE8894              GPL570       [@pone.0082241-Lee1]          138                \-                  \-                  36                     69                 62±10            75%                \-                  46/54/0                \-                        \-                             \-                      \-                \-
  GSE19188             GPL570       [@pone.0082241-Hou1]          156               30.4                 50                  \-                     \-                  \-              75%                \-                 49/30/21                \-                        \-                             \-                      \-                \-
  GSE3141              GPL570      [@pone.0082241-Bild1]          109               31.1                 58                  \-                     \-                  \-               \-                \-                  52/48/0                \-                        \-                             \-                      \-                \-
  GSE31210             GPL570    [@pone.0082241-Yamauchi1]        246               58.2                 35                 54.4                    64                60±8.1            47%                50%                 100/0/0             74/26/0/0                   90%                             \-                      \-                \-
  caArray              GPL96      [@pone.0082241-Shedden1]        462               45.8                 257                 28                     219                64±10            51%                14%                   \-                   \-                       98%                          39/47/14                   27%               21%
  TCGA                GPL3921    [@pone.0082241-Hammerman1]       133               18.3                 30                  \-                     \-                66±9.3            67%               7.5%                 0/100/0                \-                       95%                             \-                      \-                \-
  GSE29013             GPL570       [@pone.0082241-Xie1]          55                32.9                 18                 31.4                    28                64±8.7            69%               3.6%                 55/45/0            44/25/31/0                    \-                             \-                      62%               \-
  GSE37745             GPL570     [@pone.0082241-Botling1]        196               42.5                 145                 \-                     \-                64±9.2            55%                \-                 54/37/12            66/18/14/2                    \-                             \-                      \-                \-
  Entire database:      1715                 40                698/1443              37                380/821              64±10              58% (n = 886)      17.8% (n = 187)     50/45/5          63/27/10/1           95% (n = 705)          34/53/13               29% (n = 178)                   21% (n = 73)                            

OS: overall survival, FP: first progression, A/S/L: adenocarcinoma/squamous cell carcinoma/large cell carcinoma.

Set-up of online survival analysis platform {#s3b}
-------------------------------------------

We have employed Kaplan-Meier plots to visualize the association between the gene under investigation and survival. Before analysis, the patients were filtered using the available clinical parameters to include only those patients where the relevance of the gene is to be assessed. Besides filtering options specific for clinical parameters, we implemented an algorithm which includes the use of all percentiles between the lower and upper quartile to identify the best performing cutoff.

To our knowledge, present development is the very first system enabling real-time multivariate survival analysis of genes in available transcriptomic cohorts.

Validation of previously published NSCLC biomarkers {#s3c}
---------------------------------------------------

We identified 21 previously published survival associated individual genes and 7 gene expression signatures (listed in **[Table S1](#pone.0082241.s001){ref-type="supplementary-material"}**). Each of these biomarker candidates were investigated in a cohort having similar clinical characteristics as the patients in which they were originally described. For genes measured by several probe sets on the microarrays, those with the highest quality were used (high quality: average expression over 500 or maximal expression over 1000, low quality: average expression below 100, intermediate: all other probes). In case there were several high quality probes then the best performing was used. The analysis results are presented in [**Table 2**](#pone-0082241-t002){ref-type="table"} and [**Figure 2**](#pone-0082241-g002){ref-type="fig"}.

![Validation of 29 previously published NSCLC biomarkers.\
Meta-analysis of these genes and signatures in the respective sample cohort yielded CCNE1, CDC2 and CADM1 as the best performing individual genes **(A--C)** and the signature of Yamauchi et al. **(D)**. A funnel plot depicting the hazard ratios (with confidence intervals) versus sample number for CDC2 and VEGF shows more reliable estimation with larger database sizes **(E--F)**.](pone.0082241.g002){#pone-0082241-g002}

10.1371/journal.pone.0082241.t002

###### Performance of previously published biomarker candidates associated with survival in non-small-cell lung cancer.

![](pone.0082241.t002){#pone-0082241-t002-2}

  Gene                                                                Literature data         Meta-analysis results                                                                                                                                                                   
  ------------------------------------------------------------- ---------------------------- ----------------------- ---------------------- ---------------------------- ----------------------------------------------------------------------- ------ -------- ------ ------------- ----------
  **Genes examined in a meta-analysis**                                                                                                                                                                                                                                               
  VEGF                                                             [@pone.0082241-Zhan1]              5386                IHC, RT-PCR                  NSCLC                                          211527_x\_at                                1404    244     1.9      3.3e-10     \<1e-16
  MMP9                                                             [@pone.0082241-Peng1]              2029                IHC, RT-PCR                  NSCLC                                          203936_s\_at                                1404    1865    1.21      0.012         \-
                                                                                                                                                        ADE                                                                                       486     734     1.51      0.02          \-
  CCNE1 *cyclin E*                                                 [@pone.0082241-Huang1]             2606                    IHC                      NSCLC                                            213523_at                                 1404    276     1.59     2.3e-09      0.0096
                                                                                                                                                        ADE                                                                                       486     167     2.44   4.8e-08^\#^    0.0013
  BIRC5 *survivin*                                                 [@pone.0082241-Zhang1]             2703              IHC, FISH RT-PCR           NSCLC stage 2                                      202095_s\_at                                185     295     1.56      0.077         \-
  CDC2 *CDK1*                                                      [@pone.0082241-Zhang2]             2731                IHC, RT-PCR                  NSCLC                                          210559_s\_at                                1404    266     2.56   \<1e-16^\#^    0.0019
  **Genes identified in original studies**                                                                                                                                                                                                                                            
  CADM1                                                           [@pone.0082241-Botling1]             617                Array + IHC                   ADE                                             209031_at                                 486     1793    0.38    7e-12^\#^     0.0001
  CEA                                                              [@pone.0082241-Ford1]               97                     IHC                      NSCLC                                            206199_at                                 1404    110     1.21      0.02          \-
  RAD51                                                            [@pone.0082241-Qiao1]               383                    IHC                      NSCLC                                            205023_at                                 1404     44     1.4      2.4e-05       0.24
                                                                                                                                                        ADE                                                                                       486      34     1.36      0.046         \-
                                                                                                                                                        SCC                                                                                       421      45     1.2       0.18          \-
  CDKN2A *P16*                                                      [@pone.0082241-Jin1]               106                    IHC                      NSCLC                                          209644_x\_at                                1404    1382    1.65     1.8e-09       0.12
                                                                                                                                                        ADE                                                                                       486     486     2.23     6.8e-08      0.012
  OPN                                                            [@pone.0082241-Chambers1]             25                     IHC                   All patients                                      209875_s\_at                                1404    4151    1.5      2.8e-06      0.0001
                                                                 [@pone.0082241-Schneider1]            82                    RT-PCR          NSCLC surgical margin neg.                                                                           704     4101    1.93     1.5e-06      0.0032
  EZH2                                                             [@pone.0082241-Huqun1]              106                    IHC                  NSCLC stage 1                                      203358_s\_at                                440     600     2.07     2.6e-06       0.32
  IFNAR2                                                          [@pone.0082241-Tanaka1]              113                    IHC                    NSCLC PFS                                        204785_x\_at                                764     799     1.41     0.0012        0.05
  ANXA3                                                             [@pone.0082241-Liu1]               125                MS, 2D-DIGE                   ADE                                             209369_at                                 486     811     0.49     9.2e-07      0.0093
  S100A4                                                           [@pone.0082241-Tsuna1]              400                    IHC                       SCC                                           203186_s\_at                                421     2844    1.24      0.12          \-
  ADAM28                                                          [@pone.0082241-Kuroda1]              90                    ELISA                     NSCLC                                            205997_at                                 1404    143     0.69     8.3e-06      0.003
  XIAP                                                           [@pone.0082241-Ferreira1]             144                    IHC                      NSCLC                                          206536_s\_at                                1404     85     0.86      0.071         \-
  XAF1                                                             [@pone.0082241-Chen1]               51                    RT-PCR                     SCC                                             206133_at                                 421     253     0.72      0.025         \-
  CD24                                                              [@pone.0082241-Lee2]               267                    IHC                       ADE                                           209772_s\_at                                486     618     2.45     3.6e-10     \<1e--16
  ERCC1                                                            [@pone.0082241-Simon1]              51                    RT-PCR                    NSCLC                                            203719_at                                 1404    685     1.65     1.4e-10     \<1e-16
  HER2                                                           [@pone.0082241-Brabender1]            83                    RT-PCR                    NSCLC                                          216836_s\_at                                1404    898     1.25     0.0057        0.12
  CD82                                                            [@pone.0082241-Adachi1]              151                   RT-PCR                    NSCLC                                          203904_x\_at                                1404    506     1.27     0.0029        0.09
  **Gene expression signatures identified using microarrays**                                                                                                                                                                                                                         
  139-gene                                                       [@pone.0082241-Yamauchi1]             253                   Array                 NSCLC stage I          see [Table S1](#pone.0082241.s001){ref-type="supplementary-material"}   440    3368.7   3.59   8.9e-16^\#^   \<1e-16
  59-gene                                                           [@pone.0082241-Xie1]               100                   Array                     NSCLC              see [Table S1](#pone.0082241.s001){ref-type="supplementary-material"}   1404   4038.6   0.66     9.9e-08      0.035
  15-gene                                                           [@pone.0082241-Zhu1]               133               Array + RT-PCR            NSCLC + chemo          see [Table S1](#pone.0082241.s001){ref-type="supplementary-material"}   173    573.7    0.6       0.042         \-
  50-gene                                                         [@pone.0082241-Raponi1]              129            Array + RT-PCR + IHC              SCC               see [Table S1](#pone.0082241.s001){ref-type="supplementary-material"}   421    754.3    0.65     0.0016       0.0023
  17-gene                                                           [@pone.0082241-Hou1]               91                    Array                     NSCLC              see [Table S1](#pone.0082241.s001){ref-type="supplementary-material"}   1404   618.3    1.27     0.0027        0.48
  6-gene                                                            [@pone.0082241-Lee1]               138               Array + RT-PCR              NSCLC PFS            see [Table S1](#pone.0082241.s001){ref-type="supplementary-material"}   764    543.5    0.77      0.017         \-
  38-gene                                                         [@pone.0082241-Shedden1]             462                   Array                      ADE               see [Table S1](#pone.0082241.s001){ref-type="supplementary-material"}   468    437.7    0.64     0.0031       0.092

ADE: adenocarcinoma; SCC: squamous cell carcinoma; 2D-DIGE: two-dimensional difference gel electrophoresis; MS: mass spectrometry; n: number of tumor samples included in the study; \*highest quality probe, when several high quality probes then the best performing; ^\#^ see [Figure 2](#pone-0082241-g002){ref-type="fig"}. for the survival plots; ✠ of the univariate analysis; multivariate: using those two parameters where most data was available (histology and gender for NSCLC, gender and stage for adenocarcinoma and squamous cell carcinoma). Multivariate analysis was performed only for biomarker candidates significant at p\<0.01 in the univariate analysis.

Discussion {#s4}
==========

The importance of cancer biomarkers is highlighted by the success of the HER2 gene in breast cancer. High HER2 expression was first a marker of worse survival, but the introduction of targeted anti-HER2 therapy changed the picture: today HER2 positive patients have an improved prognosis compared to women with HER2 negative disease [@pone.0082241-Dawood1].

Here, by using an integrated database of ten previously published transcriptomic datasets, we validated the association with survival for a set of genes in non-small-cell lung cancer. Generally, the strongest associations were found for those also investigated in a previous meta-analysis (VEGF, CCNE1 and CDK1). For all of these genes higher expression was associated with shorter survival. With over 5,000 patients, the meta-analysis for VEGF [@pone.0082241-Zhan1] employed the highest number of patients -- our analysis also confirmed the correlation of VEGF expression and overall survival in NSCLC patients by both univariate and multivariate analyses. The importance of VEGF is due to the availability of targeted agents directly inhibiting its activation. Interestingly, for one of the genes (CDK1) a previous meta-analysis actually rejected a correlation between the gene and survival [@pone.0082241-Zhang2]. In contrast, our results represent a large-scale independent validation of the gene. In individual genes, only a few were associated with longer survival when displaying higher expression -- these include CADM1, ANXA3, ADAM28, XIAP and XAF1. Future therapeutic targeting of these will only be possible using a different approach than for most genes in which higher expression actually results in shorter survival.

After surgery, about two-thirds of recurrences for early stage disease occur at distant sites. Therefore, the eradication of micrometastases must have a high priority as early as possible. A previous meta-analysis of all the trials investigating chemotherapy benefit demonstrated a 5% improvement in overall survival [@pone.0082241-Pignon1]. This survival advantage with chemotherapy was also maintained at 9 years of follow-up. For these reasons the use of adjuvant chemotherapy is the current standard of care for patients with early stage NSCLC. In our analysis system we have integrated the use of chemotherapy to enable the validation of genes specifically related to survival in chemotherapy treated patients.

A major etiological factor for lung cancer is cigarette smoking which accounts for nearly 85% of all cases. Lung cancer development is similar to other cancer types by involving a stepwise progression to a malignant transformation driven by the collective effect of genetic changes induced by inhaled carcinogens [@pone.0082241-Boyle1]. At the same time, the number of previously never-smoker lung cancer patients is also increasing [@pone.0082241-Wakelee1]. Gathering new insights into the underlying mechanism and etiological factors in these patients is necessary to better understand the disease and to develop new treatment strategies [@pone.0082241-Ramalingam1]. In our database we had the smoking history for 1,042 patients (of these 187 never smoker) and the meta-analysis tool also includes the option to restrict to either smoker on nonsmoker cohorts of patients. Additional filtering options include the use of gender (data is available for 1,564 patients) and staging (697 patients). Combinations of these options enable to validate biomarker candidates in sub-cohorts having a size not reached by any of the previous individual studies.

Previously, within the directors\' challenge project for lung adenocarcinoma, the combined use of clinical and gene expression information performed best for predicting prognosis [@pone.0082241-Shedden1]. The multivariate analysis in the online software enables to compare clinical and molecular variables. Unfortunately, not all clinical information is published for each patient - this significantly limits the potential of any multivariate analysis including both clinical and gene expression variables.

We must also mention some issues with meta-analyses that may undermine their validity - these include biases related to patient selection, to clinical heterogeneity, to different outcome measures, to methodological and statistical techniques [@pone.0082241-Trikalinos1]. One option the test for biases is plotting the sample size against the effect size as this is usually skewed and asymmetrical in the presence a bias [@pone.0082241-Sterne1]. Basically, without a bias, the largest variation should be observed most in the small studies and least in large studies. This is the concept of the original funnel plot which we employed to demonstrate the correlation between hazard rates and sample sizes for two selected genes. We added an analysis option to our tool to run the computations in each dataset separately to enable swift construction of such analyses for any gene.

Finally, we have also assessed previously published gene expression signatures to predict survival. Today, the clinical application of multigene signatures is still controversial, as many of them do not outperform prognostication using conventional parameters. Here, out of seven signatures, two were capable to predict survival in stage I [@pone.0082241-Yamauchi1], and in all NSCLC patients [@pone.0082241-Xie1].

In summary, by utilizing genome-wide microarray datasets published in the last five years, we have successfully integrated a large scale database suitable for the *in silico* validation of biomarker candidates in non-small cell lung cancer.
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